Gabapentin treatment for alcohol dependence: a randomized clinical trial - PubMed (original) (raw)

Randomized Controlled Trial

Gabapentin treatment for alcohol dependence: a randomized clinical trial

Barbara J Mason et al. JAMA Intern Med. 2014 Jan.

Abstract

Importance: Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics.

Objective: To determine if gabapentin, a widely prescribed generic calcium channel/γ-aminobutyric acid-modulating medication, increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner.

Design, participants and setting: A 12-week, double-blind, placebo-controlled, randomized dose-ranging trial of 150 men and women older than 18 years with current alcohol dependence, conducted from 2004 through 2010 at a single-site, outpatient clinical research facility adjoining a general medical hospital.

Interventions: Oral gabapentin (dosages of 0 [placebo], 900 mg, or 1800 mg/d) and concomitant manual-guided counseling.

Main outcomes and measures: Rates of complete abstinence and no heavy drinking (coprimary) and changes in mood, sleep, and craving (secondary) over the 12-week study. RESULTS Gabapentin significantly improved the rates of abstinence and no heavy drinking. The abstinence rate was 4.1% (95% CI, 1.1%-13.7%) in the placebo group, 11.1% (95% CI, 5.2%-22.2%) in the 900-mg group, and 17.0% (95% CI, 8.9%-30.1%) in the 1800-mg group (P = .04 for linear dose effect; number needed to treat [NNT] = 8 for 1800 mg). The no heavy drinking rate was 22.5% (95% CI, 13.6%-37.2%) in the placebo group, 29.6% (95% CI, 19.1%-42.8%) in the 900-mg group, and 44.7% (95% CI, 31.4%-58.8%) in the 1800-mg group (P = .02 for linear dose effect; NNT = 5 for 1800 mg). Similar linear dose effects were obtained with measures of mood (F2 = 7.37; P = .001), sleep (F2 = 136; P < .001), and craving (F2 = 3.56; P = .03). There were no serious drug-related adverse events, and terminations owing to adverse events (9 of 150 participants), time in the study (mean [SD], 9.1 [3.8] weeks), and rate of study completion (85 of 150 participants) did not differ among groups.

Conclusions and relevance: Gabapentin (particularly the 1800-mg dosage) was effective in treating alcohol dependence and relapse-related symptoms of insomnia, dysphoria, and craving, with a favorable safety profile. Increased implementation of pharmacological treatment of alcohol dependence in primary care may be a major benefit of gabapentin as a treatment option for alcohol dependence.

Trial registration: clinicaltrials.gov Identifier: NCT00391716.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Flow of participants through the trial.

Figure 2

Figure 2

Gabapentin effects on rates of no heavy drinking and complete abstinence during the 12-week study in the intention-to-treat population (N = 150).

Figure 3

Figure 3

Gabapentin effects on number of drinks per week and number of heavy drinking days per week during the 12-week study in the intention-to-treat population (N = 150).

Figure 4

Figure 4

Gabapentin effects on standardized measures of craving, sleep, and mood during the 12-week study in the intention-to-treat population (N = 150).

Comment in

Similar articles

Cited by

References

    1. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. The Lancet. 2009;373(9682):2223–33. - PubMed
    1. Substance Abuse and Mental Health Services Administration . Results from the 2006 national survey on drug use and health: national findings. Rockville, MD: 2007. [Accessed February 10, 2013]. Office of Applied Studies (NSDUH Series H-32, DHHS publication No. SMA 07-4293). http://www.samhsa.gov/data/nsduh/2k6nsduh/2k6results.pdf.
    1. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–9. - PMC - PubMed
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition, Text Revision. American Psychiatric Press; Washington, DC: 2000.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition. American Psychiatric Press; Washington, DC: 2013.

Publication types

MeSH terms

Substances

LinkOut - more resources